Fiche centre
Virginia Commonwealth University
Richmond — United States
Essais liés25clinical trials
VilleRichmondlocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT05268289
Essais cliniques associés
25| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| PsyMINT — mHealth Intervention for Pain Self Management | Alzheimer | Non applicable | NCT07332377 | PsyMINT — mHealth Intervention for Pain Self Management | COMPLETED |
| Lab Assay for seven genetic variants for Parkinson's Disease | Parkinson | À vérifier | NCT04994015 | Parkinson's Foundation PD GENEration Genetic Registry | RECRUITING |
| AOC 1001 | Myopathies | Phase 2 | NCT05479981 | MARINA-OLE — Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients | COMPLETED |
| AOC 1001 (del-desiran) | Myopathies | Phase 3 | NCT06411288 | HARBOR — Global Study of Del-desiran for the Treatment of DM1 | COMPLETED |
| GRASP-01-002 — Defining Endpoints in Becker Muscular Dystrophy | Myopathies | À vérifier | NCT05257473 | GRASP-01-002 — Defining Endpoints in Becker Muscular Dystrophy | ACTIVE_NOT_RECRUITING |
| Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) | Myopathies | À vérifier | NCT03981575 | Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) | RECRUITING |
| ASPIRE-DM1 — DMCRN-02-001: Assessing Pediatric Endpoints in DM1 | Myopathies | À vérifier | NCT05224778 | ASPIRE-DM1 — DMCRN-02-001: Assessing Pediatric Endpoints in DM1 | RECRUITING |
| Atogepant | Migraine | Phase 3 | NCT03777059 | 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine | COMPLETED |
| CNP-106 | Myasthénie | Phase 1/2 | NCT06106672 | Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis | ACTIVE_NOT_RECRUITING |
| AOC 1020 | Myopathies | Phase 2 | NCT06547216 | FORTITUDE-OLE — Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) | ACTIVE_NOT_RECRUITING |
| AOC 1020 | Myopathies | Phase 1/2 | NCT05747924 | FORTITUDE — Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) | COMPLETED |
| Iptacopan (part 1) | Lupus | Phase 2 | NCT05268289 | Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V | RECRUITING |
| Acoramidis | Alzheimer | Phase 3 | NCT06563895 | Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant | RECRUITING |
| bemdaneprocel | Parkinson | Phase 3 | NCT06944522 | exPDite-2 — A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease | RECRUITING |
| ASSESS ALL ALS Study | Sclérose latérale amyotrophique | À vérifier | NCT06578195 | ASSESS ALL ALS Study | RECRUITING |
| PREVENT ALL ALS Study | Sclérose latérale amyotrophique | À vérifier | NCT06581861 | PREVENT ALL ALS Study | RECRUITING |
| BBP-418 | Myopathies | Phase 2 | NCT04800874 | Study of BBP-418 in Patients With LGMD2I | ACTIVE_NOT_RECRUITING |
| Del-desiran (AOC 1001) | Myopathies | Phase 3 | NCT07008469 | HARBOR-OLE — Global Open-Label Extension Study of Del-desiran for the Treatment of DM1 | ENROLLING_BY_INVITATION |
| AOC-1020 | Myopathies | Phase 3 | NCT07038200 | FORTITUDE-3 — A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD | RECRUITING |
| END-EXT — Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Extension | Myopathies | À vérifier | NCT07700225 | END-EXT — Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Extension | RECRUITING |
| TREAT-EXT — Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy Extension | Myopathies | À vérifier | NCT06747884 | TREAT-EXT — Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy Extension | RECRUITING |
| DYNE-251 | Myopathies | Phase 1/2 | NCT05524883 | DELIVER — Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping | ACTIVE_NOT_RECRUITING |
| Remibrutinib oral treatment | SEP | Phase 3 | NCT06846281 | Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. | RECRUITING |
| Early Highly Effective Therapies Group | SEP | Phase 4 | NCT03535298 | DELIVER-MS — Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS | ACTIVE_NOT_RECRUITING |
| Descartes-08 | Myasthénie | Phase 2 | NCT04146051 | Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) | ACTIVE_NOT_RECRUITING |